Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: END034
MIFTS: 32

Endocrine Exophthalmos

Categories: Eye diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Endocrine Exophthalmos

About this section

MalaCards integrated aliases for Endocrine Exophthalmos:

Name: Endocrine Exophthalmos 12 15
Thyroid Associated Opthalmopathies 74
Endocrine Exopthalmos 74

Classifications:

MalaCards categories:
Anatomical: Eye diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:12359
ICD9CM 36 376.2
SNOMED-CT 69 53061005
Sources

Summaries for Endocrine Exophthalmos

About this section
MalaCards based summary : Endocrine Exophthalmos, also known as thyroid associated opthalmopathies, is related to exophthalmos and graves' disease. An important gene associated with Endocrine Exophthalmos is TG (Thyroglobulin), and among its related pathways/superpathways is Aldosterone synthesis and secretion. The drugs Propylthiouracil and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include thyroid, eye and liver, and related phenotype is adipose tissue.

Wikipedia : 77 Graves ophthalmopathy (also known as thyroid eye disease (TED), dysthyroid/thyroid-associated... more...

Sources

Related Diseases for Endocrine Exophthalmos

About this section

Diseases related to Endocrine Exophthalmos via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
# Related Disease Score Top Affiliating Genes
1 exophthalmos 10.8
2 graves' disease 10.0
3 elastosis perforans serpiginosa 9.9
4 myxedema 9.9
5 graves disease 1 9.9
6 acute thyroiditis 9.8 POMC TG
7 hypoadrenalism 9.8 POMC TG
8 thyroid crisis 9.8 POMC TG
9 hypothyroidism 9.8 POMC TG
10 hypothyroidism, congenital, nongoitrous, 4 9.8 POMC TG
11 thyroid gland disease 9.7 POMC TG
12 cell type benign neoplasm 9.7 POMC TG
13 thyroid carcinoma, familial medullary 9.7 POMC TG
14 thyroid cancer, nonmedullary, 2 9.6 POMC TG
15 thyroid cancer 9.5 POMC TG

Graphical network of the top 20 diseases related to Endocrine Exophthalmos:



Diseases related to Endocrine Exophthalmos
Sources

Symptoms & Phenotypes for Endocrine Exophthalmos

About this section

MGI Mouse Phenotypes related to Endocrine Exophthalmos:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 8.62 POMC TG
Sources

Drugs & Therapeutics for Endocrine Exophthalmos

About this section

Drugs for Endocrine Exophthalmos (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propylthiouracil Approved, Investigational Phase 4,Phase 3 51-52-5 657298
2
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
4
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
7
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
8
Acetylcholine Approved, Investigational Phase 4,Phase 2,Phase 3 51-84-3 187
9
Dinoprost tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
10
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078
11
Bimatoprost Approved, Investigational Phase 4,Phase 3,Early Phase 1 155206-00-1 5311027
12
Methimazole Approved Phase 4,Phase 1,Phase 2,Not Applicable 60-56-0 1349907
13
Propranolol Approved, Investigational Phase 4 525-66-6 4946
14
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
15
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
16
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
17
leucovorin Approved Phase 4,Not Applicable 58-05-9 143 6006
18
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
19
Methotrexate Approved Phase 4,Not Applicable 1959-05-2, 59-05-2 126941
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
21
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
22 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
24 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
25 Antithyroid Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
26 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
27 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
28 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Not Applicable
29 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
30 Methylprednisolone Acetate Phase 4,Phase 2,Phase 3,Not Applicable
31 Antiemetics Phase 4,Phase 2,Phase 3,Not Applicable
32 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
33 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
34 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
35 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
36 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
37 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
38 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Anti-Infective Agents, Local Phase 4,Phase 3
40 Triamcinolone hexacetonide Phase 4,Not Applicable
41 triamcinolone acetonide Phase 4,Not Applicable
42 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Immunosuppressive Agents Phase 4,Not Applicable
44 Triamcinolone diacetate Phase 4,Not Applicable
45 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
46 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Botulinum Toxins Phase 4,Phase 2,Phase 3
49 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 3
50 Acetylcholine Release Inhibitors Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4 Propylthiouracil
2 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4 methylprednisolone, prednisone
3 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
4 99Tc-MDP for Thyroid-Associated Ophthalmopathy Completed NCT03948191 Phase 4 Methylprednisolone;99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
5 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
6 Liver Function After Intravenous Methylprednisolone Administration Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
7 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
8 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4 Prednisolone
9 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Recruiting NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
10 Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Recruiting NCT03107078 Phase 4 Glucocorticoids
11 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
12 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
13 A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Not yet recruiting NCT03098225 Phase 4 Methylprednisolone
14 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Withdrawn NCT01927406 Phase 4 Prostaglandin Analog;Timolol
15 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Withdrawn NCT01272414 Phase 4 Botulinum Toxin Type A;Saline injection
16 Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
17 Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease Unknown status NCT00370734 Phase 2, Phase 3 Botulinum toxin A injection
18 The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions Unknown status NCT01204359 Phase 3
19 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3 Rituximab;Saline;Methylprednisolone
20 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Completed NCT02155049 Phase 3 bimatoprost 0.03%
21 Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed NCT01297699 Phase 3 Tocilizumab (RoActemra®);Sterile 0.9% Sodium Chloride
22 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Recruiting NCT01579539 Phase 3 Methylprednisolone;Esomeprazole
23 Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Recruiting NCT03066076 Phase 3 Antithyroid Drug
24 Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS) Recruiting NCT03131726 Phase 3 Simvastatin 40mg
25 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
26 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Active, not recruiting NCT03298867 Phase 3
27 Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study Enrolling by invitation NCT03461211 Phase 3
28 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3 ASTED
29 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3 Methylprednisolone + ASTED;Methylprednisolone +Placebo
30 Doxycycline Treatment in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
31 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
32 Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease Completed NCT01868997 Phase 2 teprotumumab;normal saline
33 Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Completed NCT00424151 Phase 1, Phase 2 Rituximab
34 Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Completed NCT01727973 Phase 1, Phase 2 Doxycycline
35 Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
36 Celecoxib for Thyroid Eye Disease Recruiting NCT02845336 Phase 2 Celecoxib;artificial tears
37 Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy ( GO ) Recruiting NCT03922321 Phase 2 RVT-1401 (Administered via subcutaneous injection)
38 Effects of Atorvastatin in Graves' Orbitopathy (GO) Not yet recruiting NCT03110848 Phase 2 Atorvastatin;Methylprednisolone
39 Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO ) Not yet recruiting NCT03938545 Phase 2 RVT-1401 (Administered via subcutaneous injection)
40 A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease Terminated NCT01114503 Phase 2 Otelixizumab - low dose;Otelixizumab - medium low dose;Otelixizumab - medium high dose;Otelixizumab - high dose;Otelixizumab;Methylprednisolone
41 Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment Terminated NCT00288522 Phase 2 Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
42 Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy Withdrawn NCT01379196 Phase 1, Phase 2 Azithromycin
43 K1-70 - A Study in Subjects With Graves' Disease Recruiting NCT02904330 Phase 1 K1-70 intramuscular
44 Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy Unknown status NCT01999790 Not Applicable
45 Selenium in Mild Thyroid Eye Disease in North America Unknown status NCT02112643 Not Applicable
46 Local Triamcinolone Injection in Active Thyroid Orbitopathy Unknown status NCT01280214 Not Applicable Triamcinolone
47 The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves’Ophthalmopathy Unknown status NCT00174057
48 Genetic and Morphological Analysis of Thyrotoxic Periodic Paralysis Unknown status NCT02287363
49 Graves' Orbitopathy and Hypercholesterolemia Completed NCT02721992
50 Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy Completed NCT02766660 Not Applicable

Search NIH Clinical Center for Endocrine Exophthalmos

Sources

Genetic Tests for Endocrine Exophthalmos

About this section
Sources

Anatomical Context for Endocrine Exophthalmos

About this section

MalaCards organs/tissues related to Endocrine Exophthalmos:

42
Thyroid, Eye, Liver, Bone, B Cells, Pituitary
Sources

Publications for Endocrine Exophthalmos

About this section

Articles related to Endocrine Exophthalmos:

(show top 50) (show all 82)
# Title Authors Year
1
Surgical treatment of endocrine exophthalmos by removal of orbital fat: clinical experience. ( 12436178 )
2002
2
Optic nerve involvement in endocrine exophthalmos. ( 2079900 )
1990
3
Decompression of the orbit using a lateral rhinotomy approach in patients with malignant endocrine exophthalmos. ( 2350895 )
1990
4
Eye muscle antibodies in endocrine exophthalmos. Clinical and serological observations. ( 2744719 )
1989
5
Endocrine exophthalmos conservative management. ( 3508403 )
1987
6
Orbital decompression in endocrine exophthalmos of Graves' disease. ( 3839618 )
1985
7
T-lymphocyte-subsets in endocrine exophthalmos. ( 3879963 )
1985
8
Autoimmune endocrine exophthalmos. ( 6129469 )
1982
9
Computerized tomography in endocrine exophthalmos: report of a case. ( 6896413 )
1982
10
Endocrine exophthalmos or orbital pseudotumour. ( 6109880 )
1981
11
Endocrine exophthalmos or orbital pseudotumour. ( 6110019 )
1981
12
Serum thyroglobulin, its autoantibody and thyroid stimulating antibodies in the endocrine exophthalmos. ( 6894054 )
1981
13
Endocrine exophthalmos. ( 6894358 )
1981
14
Plasma exchange in conjunction with immunosuppressive drug therapy in the treatment of endocrine exophthalmos. ( 6896074 )
1981
15
Transantral orbital decompression for endocrine exophthalmos--an appraisal. ( 6893600 )
1980
16
Endocrine exophthalmos; conservative management. ( 6938804 )
1980
17
Progress in endocrine exophthalmos. ( 582020 )
1979
18
The pathogenesis of endocrine exophthalmos: a short review. ( 200947 )
1977
19
Endocrine exophthalmos: an immunologic aberration. ( 327376 )
1977
20
Studies in relation to endocrine exophthalmos: the biochemical composition of human retrobulbar connective tissue. ( 130249 )
1976
21
Acute endocrine exophthalmos. ( 952821 )
1976
22
Unilateral endocrine exophthalmos. Diagnostic problems in association with computed tomography. ( 980244 )
1976
23
Retrobulbar connective tissue in experimental endocrine exophthalmos. ( 126367 )
1975
24
Transantral orbital decompression for progressive endocrine exophthalmos. ( 1231082 )
1975
25
IOP and direction of gaze in endocrine exophthalmos. ( 1242210 )
1975
26
Proceedings: Endocrine exophthalmos treated by orbital decompression. ( 1242394 )
1975
27
Triiodothyronine levels in patients with euthyroid endocrine exophthalmos and during treatment of thyrotoxicosis. ( 4131145 )
1974
28
Experimental endocrine exophthalmos: II. Effect of patients' sera on radiosulfate incorporation. ( 4479728 )
1974
29
Surgical decompression of the orbit for endocrine exophthalmos. ( 4534105 )
1974
30
Experimental endocrine exophthalmos: 1. Effect of TSH on S35 sulfate uptake. ( 4858446 )
1974
31
Endocrine exophthalmos during lithium therapy of manic-depressive disease. ( 4736398 )
1973
32
Pathogenesis and treatment of endocrine exophthalmos. ( 4740436 )
1973
33
Endocrine exophthalmos. ( 4483433 )
1972
34
Medial decompression of the orbit for endocrine exophthalmos. ( 4515531 )
1972
35
Endocrine exophthalmos. ( 4550413 )
1972
36
Endocrine exophthalmos. Concepts and surgical management. ( 5007196 )
1972
37
Endocrine exophthalmos. ( 5067997 )
1972
38
Endocrine exophthalmos. ( 5078418 )
1972
39
Antral-ethmoid decompression of endocrine exophthalmos. ( 5172847 )
1971
40
Guanethidine ophthalmic solution 5 per cent. Use in the treatment of endocrine exophthalmos. ( 4912585 )
1970
41
The assessment and treatment of endocrine exophthalmos. ( 5468601 )
1970
42
Endocrine exophthalmos. ( 5537363 )
1970
43
Synergistic and inhibitory activity of various hormones on the exophthalmo producing factor in sera of patients suffering from endocrine exophthalmos. ( 4308597 )
1969
44
Mechanisms of Graves' disease and endocrine exophthalmos. ( 4895778 )
1969
45
Eight clinical varieties for endocrine exophthalmos. ( 5396087 )
1969
46
The orbital pseudotumour syndrome and its differentiation from endocrine exophthalmos. ( 5774031 )
1969
47
Investigation of endocrine exophthalmos. ( 5818230 )
1969
48
Needle aspiration of malignant (progressive) endocrine exophthalmos. ( 5699320 )
1968
49
Relationship of orbital sialic to endocrine exophthalmos. ( 4295425 )
1967
50
Tonography and visual fields in endocrine exophthalmos. Report on 29 patients. ( 6028635 )
1967
Sources

Variations for Endocrine Exophthalmos

About this section
Sources

Expression for Endocrine Exophthalmos

About this section
Search GEO for disease gene expression data for Endocrine Exophthalmos.
Sources

Pathways for Endocrine Exophthalmos

About this section

Pathways related to Endocrine Exophthalmos according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Aldosterone synthesis and secretion 38
Show member pathways
 11.49 POMC TG
Sources

GO Terms for Endocrine Exophthalmos

About this section

Biological processes related to Endocrine Exophthalmos according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 8.62 POMC TG

Molecular functions related to Endocrine Exophthalmos according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.62 POMC TG
Sources

Sources for Endocrine Exophthalmos

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....